학술논문
PCN116 - Budget Impact Analysis of Panobinostat – Bortezomib and Dexamethasone, As 3rd Or 4th Line of Treatment in Patients with Relapsed/Refractory Multiple Myeloma in Greece
Document Type
Abstract
Author
Source
In Value in Health November 2016 19(7):A729-A729
Subject
Language
ISSN
1098-3015